Trials / Completed
CompletedNCT00779428
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
Phase 2 Clinical Trial of Tanespimycin in Patients With Advanced Malignancies After Failure of Previous Anti-cancer Therapy Regimens Who Have Participated on a Prior Protocol Investigating Tanespimycin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to provide treatment to patients who have participated on a prior protocol investigating Tanespimycin (KOS-953,17-AAG)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tanespimycin | Solution, IV This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG) |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2013-03-01
- Completion
- 2013-07-01
- First posted
- 2008-10-24
- Last updated
- 2015-10-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00779428. Inclusion in this directory is not an endorsement.